Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | JUN | P05412 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31038939 | 0.83 | GABRA1 (0.50) | GABRA1GABRG2GABRB3GABRA3ADRB1 | |
| SCHEMBL17959 | 0.83 | GABRA1 (0.50) | GABRA1GABRG2GABRB3GABRA3ADRB1 | |
| SCHEMBL1661164 | 0.81 | GABRA1 (0.39) | GABRA1GABRG2GABRB3GABRA3CYP19A1 | |
| SCHEMBL31543495 | 0.81 | GABRA1 (0.39) | GABRA1GABRG2GABRB3GABRA3CYP19A1 | |
| SCHEMBL26686630 | 0.79 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRA3CYP19A1 | |
| SCHEMBL30632766 | 0.79 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRA3CYP19A1 | |
| SCHEMBL16115627 | 0.76 | GABRA1 (0.36) | GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL7171955 | 0.76 | CYP3A4 (0.46) | GABRA1GABRG2GABRB3GABRA3CYP19A1 | |
| SCHEMBL8751966 | 0.75 | TRPV4 (0.33) | ADRB1 | |
| SCHEMBL28173201 | 0.75 | SORT1 (0.36) | ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | ALTMAN MICHAEL D (US) | 2014-08-28 | — | — | US | disclosed |
| US-8759366-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8551984-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-11-01 | — | — | US | disclosed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | disclosed |
| WO-2011075517-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | GABRA1 3283/4885GABRG2 3519/4885GABRB3 4157/4885 |
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | SYK, BTK, LCK | GABRA1 3283/4885GABRG2 3519/4885GABRB3 4157/4885 |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | GABRA1 3283/4885GABRG2 3519/4885GABRB3 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.